Hariton Kousourou
Internal Medicine · Shoreham, NYNPI 1326133646
Payments from drug & device makers
Across 68 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$176
- Lilly USA, LLC$110
- AstraZeneca$83
- Lundbeck LLC$73
- Merck$60
- GSK$60
- plus $630 from 21 others
What the payments were for
- Food & beverage$1,193100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $176 |
| Lilly USA, LLC | 7 | $110 |
| AstraZeneca | 6 | $83 |
| Lundbeck LLC | 3 | $73 |
| Merck | 3 | $60 |
| GSK | 4 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $57 |
| AbbVie | 3 | $55 |
| Mylan Specialty L.p. | 3 | $51 |
| Novartis | 3 | $49 |
| Boehringer Ingelheim | 2 | $43 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Abbott | 2 | $38 |
| Sunovion Pharmaceuticals Inc. | 2 | $38 |
| Amgen | 2 | $32 |
| Insulet Corporation | 1 | $31 |
| Johnson & Johnson | 2 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$1,193 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 130 | $124,765 |
| EliquisApixaban | 138 | $116,673 |
| MounjaroTirzepatide | 82 | $91,322 |
| TrulicityDulaglutide | 76 | $90,973 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 106 | $81,971 |
| OzempicSemaglutide | 52 | $68,863 |
| MyrbetriqMirabegron | 90 | $48,652 |
| JanuviaSitagliptin Phosphate | 55 | $43,636 |
| AtivanLorazepam | 11 | $38,571 |
| XareltoRivaroxaban | 41 | $28,753 |
| OxycontinOxycodone Hcl | 13 | $27,463 |
| Xtampza ErOxycodone Myristate | 21 | $24,021 |
| VraylarCariprazine Hcl | 15 | $21,818 |
| Spiriva HandihalerTiotropium Bromide | 24 | $18,379 |
| FarxigaDapagliflozin Propanediol | 24 | $16,758 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $110 | $182,295158 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $43 | $140,050160 claims |
| PfizerEliquis | $176 | $116,673138 claims |
| GSKTrelegy Ellipta | $60 | $81,971106 claims |
| Novo NordiskOzempic | $15 | $68,86352 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $48,65290 claims |
| MerckJanuvia | $60 | $43,63655 claims |
| AbbVieVraylar, Linzess | $55 | $29,51728 claims |
| Johnson & JohnsonXarelto | $25 | $28,75341 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $14 | $24,02121 claims |
| AstraZenecaFarxiga | $83 | $16,75824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Shoreham
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.